“…Clinical studies demonstrated that EVE may prevent vascular remodeling, which is a key component of CAV [34,94,96] de novo following CTx [7,28,34,94,96,105,106] . mTOR inhibitors may provide some other beneficial ancillary anti-proliferative effects including improvement in coronary hemodynamics [28] and regression of cardiac hypertrophy, both leading to significant improvement in cardiac allograft function [100,101,107] .…”